NFT
ABVX

Nan Fung Trinity’s Abivax ABVX Stock Holding History

Nan Fung Trinity’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9M Buy
142,083
+13,143
+10% +$1.49M 1.87% 20
2026
Q1 		$14.4M Buy
128,940
+15,575
+14% +$1.84M 1.58% 27
2025
Q4 		$15.3M Buy
113,365
+12,000
+12% +$1.31M 1.21% 38
2025
Q3 		$8.61M Buy
+101,365
New +$6.21M 0.86% 42

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nan Fung Trinity's ABVX Position: Q2 2026 in Review

Nan Fung Trinity increased its Abivax (ABVX) stake by 10% in Q2 2026, buying an estimated $1.49M and bringing the position to 142,083 shares worth $18.9M. The position accounts for 1.87% of the portfolio, ranked #20.

Nan Fung Trinity first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Nan Fung Trinity held 142,083 shares of Abivax worth $18.9M as of Q2 2026.
  • Nan Fung Trinity bought 13,143 Abivax shares in Q2 2026, an estimated $1.49M.
  • Abivax made up 1.87% of Nan Fung Trinity's portfolio in Q2 2026, its #20 holding.
  • Nan Fung Trinity first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Nan Fung Trinity's 13F filing for Q2 2026, filed 24 Jul 2026.